Stanford researchers have used artificial intelligence to identify a naturally occurring molecule called BRP that significantly reduced appetite and body fat in animal experiments. The discovery could open a new direction in obesity treatment, but human trials are still needed.
Could there be a future weight-loss treatment that works like Ozempic but causes fewer digestive problems and preserves muscle? Stanford Medicine researchers are investigating a promising candidate.
The molecule, called BRP (BRINP2-related peptide), reduced food intake by up to 50% in animal experiments. It also helped obese mice lose body fat while largely preserving muscle mass.
The findings, published in the journal Nature and reported by Stanford Medicine on November 4, 2026, highlight how AI could accelerate the discovery of new obesity treatments.
What Is BRP and How Does It Work?
BRP is a tiny peptide made up of just 12 amino acids. Unlike semaglutide, the active ingredient in Ozempic and Wegovy, it appears to influence appetite through a different biological pathway.
Semaglutide mimics the GLP-1 hormone, which acts on receptors found in several parts of the body, including the brain, gut and pancreas. This helps regulate hunger and blood sugar but can also cause side effects such as nausea, vomiting and constipation.
BRP appears to act more selectively in the hypothalamus, a brain region responsible for regulating hunger, metabolism and energy balance.
Researchers believe this different mechanism could eventually offer more targeted appetite control with fewer unwanted effects. However, this possibility has not yet been established in humans.
How Did AI Help Discover the New Weight-Loss Molecule?
The Stanford team developed an AI-based computer algorithm called Peptide Predictor to search for potential hormone-like molecules.
The system examined approximately 20,000 human protein-coding genes and identified protein fragments that could be produced by an enzyme involved in hormone processing.
The initial screening narrowed thousands of possibilities to 373 candidate proteins. Researchers then predicted 2,683 peptides and experimentally tested 100 promising candidates.
BRP stood out because it increased activity in laboratory-grown nerve cells to around ten times the level seen in untreated control cells.
This AI-assisted approach helped scientists identify a promising molecule that conventional, slower screening methods might have overlooked.
BRP Weight-Loss Results: What Did Animal Studies Show?
The researchers tested BRP in mice and minipigs. The early findings were encouraging:
- Appetite suppression: Treated animals consumed up to 50% less food during the observation period.
- Fat loss: Obese mice receiving daily BRP injections for 14 days lost an average of 3 grams, while untreated mice gained approximately 3 grams.
- Muscle preservation: Nearly all the weight lost by treated mice came from body fat.
- Metabolic improvements: Researchers also observed improvements in glucose and insulin tolerance.
The team did not observe significant changes in several monitored behaviours and physical measures, including fecal output. This is particularly interesting because constipation is a known concern with some GLP-1 medications.
However, animal experiments cannot establish whether BRP will prevent nausea, constipation or other side effects in people.
Is BRP Better Than Ozempic?
It is too early to say. BRP has shown promising results in animals, but it has not yet been proven safe or effective for human weight loss.
The researchers now want to identify the exact cell-surface receptors BRP activates and find ways to make its effects last longer. Peptides can break down quickly inside the body, potentially making frequent injections necessary.
Human clinical trials will need to establish its safety, dosage, long-term effectiveness and possible side effects.
Can BRP Replace Ozempic or Wegovy?
Not at present. BRP is an experimental molecule, not an approved obesity medication. People should not consider it an alternative to prescribed weight-loss drugs until proper human trials demonstrate its benefits and risks.
Nevertheless, the discovery is significant. It shows how artificial intelligence in drug discovery could help scientists identify previously unknown biological pathways for treating obesity.
If future trials confirm the animal findings, BRP could become an interesting candidate for a new generation of weight-loss treatments that aim to reduce body fat while preserving muscle.
Medical disclaimer: This article is for educational purposes only. BRP remains experimental and is not approved for human weight-loss treatment.
Source: SD
